A LinkedIn post from Pulnovo Medical highlights the company’s plans to showcase its pulmonary artery denervation (PADN) technology and related clinical work at IndiaLive2026 in New Delhi. The post points to live case transmissions of a PADN procedure and presentations on the rationale, evidence, and case management for pulmonary hypertension across March 20–21.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The focus on PH and heart failure suggests Pulnovo is positioning its PADN platform as a differentiated interventional option in high-burden cardiovascular indications. For investors, this visibility at a major cardiology forum may support physician awareness, potential future adoption, and partnering opportunities, though near-term revenue impact remains uncertain and likely dependent on clinical outcomes, regulatory progress, and reimbursement pathways in key markets.